{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:48:51Z","timestamp":1782949731573,"version":"3.54.5"},"reference-count":61,"publisher":"Pharmaceutical Society of Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2018]]},"DOI":"10.1248\/bpb.b17-00556","type":"journal-article","created":{"date-parts":[[2017,11,26]],"date-time":"2017-11-26T22:16:32Z","timestamp":1511734592000},"page":"163-171","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy of Chondroitin Sulfate for Painful Knee Osteoarthritis: A One-Year, Randomized, Double-Blind, Multicenter Clinical Study in Japan"],"prefix":"10.1248","volume":"41","author":[{"given":"Mitsuhiro","family":"Morita","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Fujita Health University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Yamada","sequence":"additional","affiliation":[{"name":"Consumer Healthcare Products Development, Zeria Pharmaceutical Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Date","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Fujita Health University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazue","family":"Hayakawa","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Fujita Health University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetomo","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Consumer Healthcare Products Development, Zeria Pharmaceutical Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harumoto","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Fujita Health University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part 1. <i>Arthritis Rheum.<\/i>, <b>58<\/b>, 15\u201325 (2008).","DOI":"10.1002\/art.23177"},{"key":"2","unstructured":"2) Issa SN, Sharma L. Epidemiology of osteoarthritis: an update. <i>Curr. Rheumatol. Rep.<\/i>, <b>8<\/b>, 7\u201315 (2006)."},{"key":"3","unstructured":"3) Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence-based, expert consensus guidelines. <i>Osteoarthritis Cartilage<\/i>, <b>16<\/b>, 137\u2013162 (2008)."},{"key":"4","unstructured":"4) Uebelhart D, Thonar EJ, Delmas PD, Chantraine A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. <i>Osteoarthritis Cartilage<\/i>, <b>6<\/b> (Suppl. A), 39\u201346 (1998)."},{"key":"5","unstructured":"5) Uebelhart D, Malaise M, Marcolongo R, DeVathaire F, Piperno M, Mailleux E, Fioravanti A, Matoso L, Vignon E. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study <i>versus<\/i> placebo. <i>Osteoarthritis Cartilage<\/i>, <b>12<\/b>, 269\u2013276 (2004)."},{"key":"6","unstructured":"6) Michel BA, Stucki G, Frey D, De Vathaire F, Vignon E, Bruehlmann P, Uebelhart D. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. <i>Arthritis Rheum.<\/i>, <b>52<\/b>, 779\u2013786 (2005)."},{"key":"7","unstructured":"7) Kahan A, Uebelhart D, De Vathaire F, Delmas PD, Reginster JY. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. <i>Arthritis Rheum.<\/i>, <b>60<\/b>, 524\u2013533 (2009)."},{"key":"8","unstructured":"8) Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE, Gossett C. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. <i>Lancet<\/i>, <b>357<\/b>, 251\u2013256 (2001)."},{"key":"9","unstructured":"9) Pavelk\u00e1 K, Gatterov\u00e1 J, Olejarov\u00e1 M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. <i>Arch. Intern. Med.<\/i>, <b>162<\/b>, 2113\u20132123 (2002)."},{"key":"10","unstructured":"10) Bruyere O, Pavelka K, Rovati LC, Gatterova J, Giacovelli G, Olejarova M, Deroisy R, Reginster JY. Total joint replacement after glucosamine sulfate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomized, placebo-controlled trials. <i>Osteoarthritis Cartilage<\/i>, <b>16<\/b>, 254\u2013260 (2008)."},{"key":"11","unstructured":"11) Dougados M, Nguyen M, Berdah L, Mazi\u00e9res B, Vignon E, Lequesne M. Evaluation of structure-modifying effects of diacerein in hip osteoarthritis: ECHODIOH, a three-year, placebo-controlled, trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip. <i>Arthritis Rheum.<\/i>, <b>44<\/b>, 2539\u20132547 (2001)."},{"key":"12","unstructured":"12) Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE, Wolfe F, Schnitzer TJ, Moreland LW, Manzi S, Bradley JD, Sharma L, Oddis CV, Hugenberg ST, Heck LW. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. <i>Arthritis Rheum.<\/i>, <b>52<\/b>, 2015\u20132025 (2005)."},{"key":"13","unstructured":"13) Raynauld JP, Martel-Pelletier J, Bias P, Laufer S, Haraoui B, Choquette D, Beaulieu AD, Abram F, Dorais M, Vignon E, Pelletier JP. Protective effects of licofelone, a lipoxygenase and cyclo-oxygenase inhibitor, <i>versus<\/i> naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. <i>Ann. Rheum. Dis.<\/i>, <b>68<\/b>, 938\u2013947 (2009)."},{"key":"14","unstructured":"14) Wieland HA, Michaelis M, Kirschbaum BJ, Rudolphi KA. Osteoarthritis: an untreatable disease? <i>Nat. Rev. Drug Discov.<\/i>, <b>4<\/b>, 331\u2013344 (2005)."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Rashad S, Revell P, Hemingway A, Low F, Rainsford K, Walker F. Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. <i>Lancet<\/i>, <b>334<\/b>, 519\u2013522 (1989).","DOI":"10.1016\/S0140-6736(89)90651-X"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Adams ME, Lussier AJ, Peyron JG. A risk-benefit assessment of injections of hyaluronan and its derivatives in the treatment of knee osteoarthritis. <i>Drug Saf.<\/i>, <b>23<\/b>, 115\u2013130 (2000).","DOI":"10.2165\/00002018-200023020-00003"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Omata T, Itokazu Y, Inoue N, Segawa Y. Effects of chondroitin sulfate-C on articular cartilage destruction in murine collagen-induced arthritis. <i>Arzneimittelforschung<\/i>, <b>50<\/b>, 148\u2013153 (2000).","DOI":"10.1055\/s-0031-1300180"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Orth MW, Peters TL, Hawkins JN. Inhibition of articular cartilage degradation by glucosamine-HCl and chondroitin sulfate. <i>Equine Vet. J. Suppl.<\/i>, <b>2002<\/b>, 224\u2013229 (2002).","DOI":"10.1111\/j.2042-3306.2002.tb05423.x"},{"key":"19","unstructured":"19) Tat SK, Pelletier JP, Verg\u00e9s J, Lajeunesse D, Montell E, Fahmi H, Lavigne M, Martel-Pelletier J. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. <i>Arthritis Res. Ther.<\/i>, <b>9<\/b>, R117 (2007)."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Chan PS, Caron JP, Orth MW. Effect of glucosamine and chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants. <i>Am. J. Vet. Res.<\/i>, <b>66<\/b>, 1870\u20131876 (2005).","DOI":"10.2460\/ajvr.2005.66.1870"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) du Souich P, Garc\u00eda AG, Verg\u00e9s J, Montell E. Immunomodulatory and anti-inflammatory effects of chondroitin sulfate. <i>J. Cell. Mol. Med.<\/i>, <b>13<\/b> (8A), 1451\u20131463 (2009).","DOI":"10.1111\/j.1582-4934.2009.00826.x"},{"key":"22","unstructured":"22) Bishnoi M, Jain A, Hurkat P, Jain SK. Chondroitin sulphate: a focus on osteoarthritis. <i>Glycoconj. J.<\/i>, <b>33<\/b>, 693\u2013705 (2016)."},{"key":"23","unstructured":"23) Morreale P, Manopulo R, Galati M, Boccanera L, Saponati G, Bocchi L. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. <i>J. Rheumatol.<\/i>, <b>23<\/b>, 1385\u20131391 (1996)."},{"key":"24","unstructured":"24) Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G, Zimmerman-Gorska I, Dougados M. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISTT). <i>Ann. Rheum. Dis.<\/i>, <b>62<\/b>, 1145\u20131155 (2003)."},{"key":"25","unstructured":"25) Leeb BF, Schweitzer H, Montag K, Smolen JS. A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. <i>J. Rheumatol.<\/i>, <b>27<\/b>, 205\u2013211 (2000)."},{"key":"26","unstructured":"26) McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. <i>JAMA<\/i>, <b>283<\/b>, 1469\u20131475 (2000)."},{"key":"27","unstructured":"27) Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. <i>Arch. Intern. Med.<\/i>, <b>163<\/b>, 1514\u20131522 (2003)."},{"key":"28","unstructured":"28) Hochberg MC, Zhan M, Langenberg P. The rate of decline of joint space width in patients with osteoarthritis of the knee: systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate. <i>Curr. Med. Res. Opin.<\/i>, <b>24<\/b>, 3029\u20133035 (2008)."},{"key":"29","unstructured":"29) Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. <i>Rheumatol. Int.<\/i>, <b>30<\/b>, 357\u2013363 (2010)."},{"key":"30","unstructured":"30) Pelletier JP, Raynauld JP, Beaulieu AD, Bessette L, Morin F, de Brum-Fernandes AJ, Delorme P, Dorais M, Paiement P, Abram F, Martel-Pelletier J. Chondroitin sulfate efficacy <i>versus<\/i> celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. <i>Arthritis Res. Ther.<\/i>, <b>18<\/b>, 256 (2016)."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Chondroitin for osteoarthritis. <i>Cochrane Database Syst. Rev.<\/i>, <b>28<\/b>, CD005614 (2015). doi: 10.1002\/14651858.CD005614.pub2","DOI":"10.1002\/14651858.CD005614.pub2"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Herrero-Beaumont G, Rom\u00e1n-Blas J, Casta\u00f1eda S, Largo R, Blanco FJ. Chondroitin sulfate plus glucosamine sulfate does not show superiority over placebo in a randomised, double blind, placebo-controlled clinical trial in patients with knee osteoarthritis. <i>Osteoarthritis Cartilage<\/i>, <b>24<\/b> (Suppl. 1), S48\u2013S49 (2016).","DOI":"10.1016\/j.joca.2016.01.111"},{"key":"33","unstructured":"33) Sawitzke AD, Shi H, Finco MF, Dunlop DD, Bingham CO 3rd, Harris CL, Singer NG, Bradley JD, Silver D, Jackson CG, Lane NE, Oddis CV, Wolfe F, Lisse J, Furst DE, Reda DJ, Moskowitz RW, Williams HJ, Clegg DO. The effect of glucosamine and\/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine\/chondroitin arthritis intervention trial. <i>Arthritis Rheum.<\/i>, <b>58<\/b>, 3183\u20133191 (2008)."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Clegg DO, Reda DJ, Harris CL, Klein MA, O\u2019dell JR, Hooper MM, Bradley JD, Bingham CO III, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR Jr, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW, Williams HJ. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. <i>N. Engl. J. Med.<\/i>, <b>354<\/b>, 795\u2013808 (2006).","DOI":"10.1056\/NEJMoa052771"},{"key":"35","unstructured":"35) Miwa T. Clinical effect of chondroitin sulfate on Indefinite Symptoms. <i>Clin. Rep.<\/i>, <b>21<\/b>, 6239\u20136245 (1987)."},{"key":"36","unstructured":"36) Pavelka K, Manopulo R, Bucsi L. Double-blind, dose-effect study of oral CS 1200, 800, 200\u2009mg and placebo in the treatment of knee osteoarthritis. <i>Litera Pheumatologica<\/i>, <b>24<\/b>, 21\u201330 (1998)."},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Validation\u2014value in comparison with other assessment tests. <i>Scand. J. Rheumatol. Suppl.<\/i>, <b>16<\/b>, 85\u201389 (1987).","DOI":"10.3109\/03009748709102182"},{"key":"38","unstructured":"38) Huskisson EC. Measurement of pain. <i>J. Rheumatol.<\/i>, <b>9<\/b>, 768\u2013769 (1982)."},{"key":"39","unstructured":"39) Tseng S, Reddi AH, Di Cesare PE. Cartilage oligomeric matrix protein (COMP): a biomarker of arthritis. <i>Biomark. Insights<\/i>, <b>4<\/b>, 33\u201344 (2009)."},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Turan Y, Bal S, Gurgan A, Topac H, Koseoglu M. Serum hyaluronan levels in patients with knee osteoarthritis. <i>Clin. Rheumatol.<\/i>, <b>26<\/b>, 1293\u20131298 (2007).","DOI":"10.1007\/s10067-006-0499-4"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Sharif M, George E, Shepstone L, Knudson W, Thonar EJ, Cushnaghan J, Dieppe P. Serum hyaluronic acid level as a predictor of disease progression in osteoarthritis of the knee. <i>Arthritis Rheum.<\/i>, <b>38<\/b>, 760\u2013767 (1995).","DOI":"10.1002\/art.1780380608"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. <i>Ann. Rheum. Dis.<\/i>, <b>16<\/b>, 494\u2013502 (1957).","DOI":"10.1136\/ard.16.4.494"},{"key":"43","unstructured":"43) Monfort J, Martel-Pelletier J, Pelletier JP. Chondroitin sulfate for symptomatic osteoarthritis: critical appraisal of meta-analyses. <i>Curr. Med. Res. Opin.<\/i>, <b>24<\/b>, 1303\u20131308 (2008)."},{"key":"44","unstructured":"44) Tsuji T, Yoon J, Kitano N, Okura T, Tanaka K. Effects of <i>N<\/i>-acetyl glucosamine and chondroitin sulfate supplementation on knee pain and self-reported knee function in middle-aged and older Japanese adults: a randomized, double-blind, placebo-controlled trial. <i>Aging Clin. Exp. Res.<\/i>, <b>28<\/b>, 197\u2013205 (2016)."},{"key":"45","unstructured":"45) Belo JN, Berger MY, Reijman M, Koes BW, Bierma-Zeinstra SMA. Prognostic factors of progression of osteoarthritis of the knee: a systematic review of observational studies. <i>Arthritis Rheum.<\/i>, <b>57<\/b>, 13\u201326 (2007)."},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Sofat N. Analysing the role of endogenous matrix molecules in the development of osteoarthritis. <i>Int. J. Exp. Pathol.<\/i>, <b>90<\/b>, 463\u2013479 (2009).","DOI":"10.1111\/j.1365-2613.2009.00676.x"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Petersson IF, Boegard T, Dahlstrom J, Svensson B, Heinegard D, Saxne T. Bone scan and serum markers of bone and cartilage in patients with knee pain and osteoarthritis. <i>Osteoarthritis Cartilage<\/i>, <b>6<\/b>, 33\u201339 (1998).","DOI":"10.1053\/joca.1997.0090"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Vil\u00edm V, Olejarova M, Machacek S, Gatterova J, Kraus VB, Pavelka K. Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis. <i>Osteoarthritis Cartilage<\/i>, <b>10<\/b>, 707\u2013713 (2002).","DOI":"10.1053\/joca.2002.0819"},{"key":"49","unstructured":"49) Haberhauer GF, Feyertag J, Kittl EM, Bauer K, Dunky A. Steroid treatment normalises the variability and levels of serum COMP in RA patients, indicating a possibility to monitor effect of cartilage protective drugs. <i>Ann. Rheum. Dis.<\/i>, <b>61<\/b> (Suppl. 1), 200 (2002)."},{"key":"50","unstructured":"50) Haberhauer GF, Feyertag J, Kitti EM, Bauer K, Dunky A. Rapid decrease of COMP serum levels in patients with active RA undergoing IV steroid treatment. <i>Ann. Rheum. Dis.<\/i>, <b>62<\/b> (Suppl. 1), 166 (2003)."},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Crnkic M, M\u00e5nsson B, Larsson L, Geborek P, Heinegard D, Saxne T. Serum cartilage oligomeric matrix protein (COMP) decreased in rheumatoid arthritis patients treated with infliximab or etanercept. <i>Arthritis Res. Ther.<\/i>, <b>5<\/b>, R181\u2013R185 (2003).","DOI":"10.1186\/ar760"},{"key":"52","unstructured":"52) den Broeder AA, Joosten LA, Saxne T, Heineg\u00e5rd D, Fenner H, Miltenburg AM, Frasa WL, van Tits LJ, Buurman WA, van Riel PL, van de Putte LB, Barrera P. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. <i>Ann. Rheum. Dis.<\/i>, <b>61<\/b>, 311\u2013318 (2002)."},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Neidhart M, Hauser N, Paulsson M, DiCesare PE, Michel BA, H\u00e4uselmann HJ. Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation. <i>Br. J. Rheumatol.<\/i>, <b>36<\/b>, 1151\u20131160 (1997).","DOI":"10.1093\/rheumatology\/36.11.1151"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Turan Y, Bal S, Gurgan A, Topac H, Koseoglu M. Serum hyaluronan levels in patients with knee osteoarthritis. <i>Clin. Rheumatol.<\/i>, <b>26<\/b>, 1293\u20131298 (2007).","DOI":"10.1007\/s10067-006-0499-4"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Sharif M, George E, Shepstone L, Knudson W, Thonar EJJ, Cushnaghan J, Dieppe P. Serum hyaluronic acid level as a predictor of disease progression in osteoarthritis of the knee. <i>Arthritis Rheum.<\/i>, <b>38<\/b>, 760\u2013767 (1995).","DOI":"10.1002\/art.1780380608"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Georges C, Vigneron H, Ayral X, Listrat V, Ravaud P, Dougados M, Sharif M, Dieppe P, Saxne T. Serum biologic markers as predictors of disease progression in osteoarthritis of the knee. <i>Arthritis Rheum.<\/i>, <b>40<\/b>, 590\u2013591 (1997).","DOI":"10.1002\/art.1780400333"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Pavelka K, Forejtov\u00e1 S, Olej\u00e1rov\u00e1 M, Gatterov\u00e1 J, Senolt L, Spacek P, Braun M, Hulejov\u00e1 M, Stov\u00edckov\u00e1 J, Pavelkov\u00e1 A. Hyaluronic acid levels may have predictive value for the progression of knee osteoarthritis. <i>Osteoarthritis Cartilage<\/i>, <b>12<\/b>, 277\u2013283 (2004).","DOI":"10.1016\/j.joca.2004.01.001"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Elliott AL, Kraus VB, Luta G, Stabler T, Renner JB, Woodard J, Dragomir AD, Helmick CG, Hochberg MC, Jordan JM. Serum hyaluronan levels and radiographic knee and hip osteoarthritis in African Americans and Caucasians in the Johnston County Osteoarthritis Project. <i>Arthritis Rheum.<\/i>, <b>52<\/b>, 105\u2013111 (2005).","DOI":"10.1002\/art.20724"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Goldberg RL, Huff JP, Lenz ME, Glickman P, Katz REJ, Thonar EJ. Elevated plasma levels of hyaluronate in patients with osteoarthritis and rheumatoid arthritis. <i>Arthritis Rheum.<\/i>, <b>34<\/b>, 799\u2013807 (1991).","DOI":"10.1002\/art.1780340704"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Inoue R, Ishibashi Y, Tsuda E, Yamamoto Y, Matsuzaka M, Takahashi I, Danjo K, Umeda T, Nakaji S, Toh S. Knee osteoarthritis, knee joint pain and aging in relation to increasing serum hyaluronan level in the Japanese population. <i>Osteoarthritis Cartilage<\/i>, <b>19<\/b>, 51\u201357 (2011).","DOI":"10.1016\/j.joca.2010.10.021"},{"key":"61","unstructured":"61) Wildi LM, Raynauld JP, Martel-Pelletier J, Beaulieu A, Bessette L, Morin F, Abram F, Dorais M, Pelletier JP. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double-blind, placebo-controlled pilot study using MRI. <i>Ann. Rheum. Dis.<\/i>, <b>70<\/b>, 982\u2013989 (2011)."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/41\/2\/41_b17-00556\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T21:06:28Z","timestamp":1570395988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/41\/2\/41_b17-00556\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b17-00556","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}